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Data for reference 
The TRACK-HD and Enroll-HD clinical data 
that support the ﬁndings of this study are 
available for approved studies from CHDI 
( https://chdifoundation.org ) and 
https://www.enroll- hd.org/for- researchers/ 
access-data/ respectively, but restrictions 
apply to the availability of these data, 
which were used under license for the 
current study, and so are not publicly 
available. The linked novel data generated 
here are available from the authors upon 
request (darren.monckton@glasgow.ac.uk), 
subject to approval from TRACK-HD and/or 
Enroll-HD as appropriate. 
a b s t r a c t 
Background: Huntington disease (HD) is caused by an unstable CAG/CAA repeat expansion encoding a 
toxic polyglutamine tract. Here, we tested the hypotheses that HD outcomes are impacted by somatic 
expansion of, and polymorphisms within, the HTT CAG/CAA glutamine-encoding repeat, and DNA repair 
genes. 
Methods: The sequence of the glutamine-encoding repeat and the proportion of somatic CAG expansions 
in blood DNA from participants inheriting 40 to 50 CAG repeats within the TRACK-HD and Enroll-HD 
cohorts were determined using high-throughput ultra-deep-sequencing. Candidate gene polymorphisms 
were genotyped using kompetitive allele-speciﬁc PCR (KASP). Genotypic associations were assessed using 
time-to-event and regression analyses. 
Findings: Using data from 203 TRACK-HD and 531 Enroll-HD participants, we show that individuals 
with higher blood DNA somatic CAG repeat expansion scores have worse HD outcomes: a one-unit in- 
crease in somatic expansion score was associated with a Cox hazard ratio for motor onset of 3 ·05 (95% 
CI = 1 ·94 to 4 ·80, p = 1 ·3 × 10 −6 ). We also show that individual-speciﬁc somatic expansion scores are 
associated with variants in FAN1 ( pFDR = 4 ·8 ×10 -6 ), MLH3 ( pFDR = 8 ·0 ×10 −4 ), MLH1 ( pFDR = 0 ·004) and 
MSH3 ( pFDR = 0 ·009). We also show that HD outcomes are best predicted by the number of pure CAGs 
rather than total encoded-glutamines. 
Interpretation: These data establish pure CAG length, rather than encoded-glutamine, as the key inherited 
determinant of downstream pathophysiology. These ﬁndings have implications for HD diagnostics, and 
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support somatic expansion as a mechanistic link for genetic modiﬁers of clinical outcomes, a driver of 
disease, and potential therapeutic target in HD and related repeat expansion disorders. 
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Research in context 
Evidence before this study 
Huntington disease (HD), a devastating neurodegenerative con- 
dition with a prevalence of ∼1/10 0 0 0, is caused by the expan- 
sion of a CAG/CAA repeat in exon one of the HTT gene. The ex- 
panded CAG/CAA tract encodes for glutamine in the HTT protein, 
and pathology is assumed to primarily result as a toxic gain of 
function of the mutant polyglutamine containing protein. More re- 
peats cause an earlier age at onset, however, measured inherited 
CAG length only accounts for ∼60% of the variation in age at onset. 
We sought to identify genetic variants that modify residual varia- 
tion in HD outcomes not accounted for by measured CAG length 
and determine their mode of action. All searches were conducted 
in PubMed for articles published from January 1st 1984 until April 
30th 2019. Language was not restricted, however, PubMed is bi- 
ased toward English language journals. Nonetheless, although rare, 
HD is a high-proﬁle disorder and recent important genetic stud- 
ies are likely to have been published in English. Initially, we used 
the search terms “Huntington ∗ disease” AND “modiﬁer gene” AND 
species “human” AND publication type NOT “review”. This identi- 
ﬁed 53 reports, most of which were candidate gene studies that 
were superseded by two genome-wide association studies (GWAS). 
These revealed genome-wide signiﬁcant hits at the RRM2B/UBR5, 
FAN1 and MSH3 loci, and a highly suggestive hit at the MLH1 locus 
that was conﬁrmed in a follow-up study. As some of these genes 
are known modiﬁers of somatic expansion in animal models, these 
data suggested that their effects on disease severity might be me- 
diated through somatic expansion of the CAG repeat. We thus also 
used the search terms “Huntington ∗ disease” AND “somatic expan- 
sion” AND species “human” and publication type NOT “review”. 
This identiﬁed 55 reports, most of which were studies in other dis- 
eases or model organisms, or small-scale largely non-quantitative 
analyses of somatic expansion in HD patients. Several critical stud- 
ies reported large expansions in HD patient brains, with one key 
study revealing an association between the degree of skewness 
of somatic expansions in the cortex of end-stage patients and ex- 
treme variation in age at onset. There were no large-scale system- 
atic quantitative analyses of the frequency of somatic expansions in 
the peripheral tissues of HD patients. It is well known in other dis- 
orders that the presence of variant repeat interruptions within the 
repeat array can modulate the germline instability of repeat expan- 
sions. Using the search terms “Huntington ∗ disease” AND “repeat 
interruption” AND species “human” and publication type NOT “re- 
view” revealed no studies. However, we were aware of two 1995 
reports by Pêcheux et al., and Goldberg et al., describing atypical 
structures of the HTT exon one CAG/CAA repeat. These studies were 
subsequently cited in 146 publications, eight of which described 
rare sequence variants in the HTT exon one repeat. Articles citing 
these studies were investigated, revealing one additional study de- 
scribing an atypical HTT exon one repeat allele. All of these studies 
were small, mostly anecdotal case reports, and none provided any 
quantitative data in support of an effect on HD clinical outcomes. 
Some available evidence suggests that loss of the CAA repeat inter- 
ruption might be associated with an increased risk of intergenera- 
tional expansion of intermediate alleles (27 to 35 CAG repeats), but 
none of the studies was powered to provide a deﬁnitive answer to 
this question. None of the studies reported any effect of the pres- 
ence or absence of repeat sequence interruptions on the somatic 
instability of HTT alleles. 
Added value of this study 
We present a high-throughput ultra-deep sequencing method 
to reveal the frequency of synonymous CAA repeat interruptions in 
the HTT CAG/CAA repeat and determined that pure CAG length, not 
total encoded-glutamine number, better explains clinical outcomes 
in HD, and that mis-sizing of the expanded pure CAG tract using 
standard fragment length may yield misleading estimates of pre- 
dicted HD outcomes. We precisely quantiﬁed the ratio of somatic 
CAG expansions in blood DNA, and revealed that somatic expan- 
sions are also better predicted by pure CAG length, and that in- 
dividuals with more somatic expansions tend to have worse clini- 
cal outcomes, including an earlier age at onset, higher baseline to- 
tal motor score and, in TRACK-HD, higher progression scores. We 
also established that variants in DNA repair genes FAN1, MSH3 and 
MLH1, previously identiﬁed by GWASs of HD onset and progres- 
sion, and MLH3, previously implicated by pathway analysis and 
animal models, are associated with somatic expansion scores in 
blood DNA. 
Implications of all the available evidence 
These data suggest that consideration should be given in the 
future to potentially replacing fragment length analysis using a 
sequence-based approach to genotyping HD in order to improve 
diagnostic accuracy, prognostic precision and the power of clinical 
trials. This might be particularly clinically relevant for people with 
repeat lengths close to the pathological threshold, as a sequence- 
based approach would reduce ambiguity and the risk of false- 
positive/negative test results. Combined with previous data on the 
intergenerational instability of HTT alleles lacking CAA repeat in- 
terruptions, these data suggest that sequence-level genotypes will 
also enable provision of more accurate risk assessments to off- 
spring for prospective parents. These data reveal CAG length as a 
more accurate predictor of disease outcomes rather than encoded- 
glutamine repeat length. This has implications for understanding 
the pathogenic events in HD, and the interpretation of apparently 
disease-moderating repeat interruptions in related disorders also 
caused by the expansion of polyglutamine-encoding CAG repeats 
which may also act through effects on somatic expansion rather 
than the assumed effects on protein structure. They also support a 
novel approach to therapy via gene editing, by introduction of syn- 
onymous DNA-stabilising interruptions. Our data establish somatic 
expansion in blood DNA as a molecular phenotype, and, combined 
with previous data on somatic expansion of the HTT CAG repeat 
in brain and animal models, suggest that some genetic modiﬁers 
of HD clinical outcomes may operate via effects on somatic ex- 
pansion of the CAG repeat. Combined, these data support somatic 
expansion of the CAG repeat as a novel therapeutic target in HD, 
and likely in other repeat expansion disorders, reveal a potential 
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peripheral biomarker of somatic expansion for clinical trials, and 
highlight FAN1, MLH1, MSH3 and MLH3 as potential drug targets. 
1. Introduction 
Huntington disease (HD) is one of a number of disorders in- 
cluding many of the spinocerebellar ataxias, dentatorubral palli- 
doluysian atrophy, and spinal and bulbar muscular atrophy, caused 
by the expansion of a genetically unstable CAG/CAA repeat encod- 
ing a toxic polyglutamine protein and characterised by extreme 
variability in age at onset (AAO) [1] . HD is caused by the expan- 
sion of a CAG repeat in exon one of HTT and the most common 
allele in Europeans is 17 CAG repeats. HD-associated alleles exceed 
35 CAG repeats and penetrance increases to ∼100% by 40 repeats 
[2,3] . HD alleles are unstable in the germline and frequently in- 
crease in length from one generation to the next, with inheritance 
of a single CAG increase reducing AAO by ∼2 years [2] . Disease- 
associated alleles also display allele length-, age- and cell type- 
dependent, and expansion-biased, somatic instability, with somatic 
expansions exceeding 10 0 0 CAG repeats in some striatal neurons 
[4–8] . Although somatic expansion could provide an explanation 
for the tissue-speciﬁcity and progressive nature of symptoms [4] , 
it has not been widely considered as a therapeutic target in HD 
[9] and related disorders. However, recent data arising from an un- 
biased genome-wide association study (GWAS) revealed signals in 
DNA repair pathways as modiﬁers of age at onset [10] , some of 
which have previously been revealed as mediating somatic expan- 
sions in mouse models [1] . 
In a typical HTT allele, the pure CAG repeat (CAG copy num- 
ber = Q 1 ) is followed immediately downstream by an additional 
glutamine-encoding CAACAG cassette (number of additional glu- 
tamines encoded by this region = Q 2 , Fig. 2 , Table 1 ). Thus, the 
total number of consecutive glutamines encoded by this region 
(Q T ) is typically equal to the number of pure CAGs, plus two 
(Q T = Q 1 + Q 2 ). The standard approach to genotyping in HD is to 
use PCR and fragment length analysis to infer the number of pure 
CAGs (Q FL ) assuming the typical allele structure ( i.e. Q 1 = Q FL , as- 
suming Q 2 = 2) [11] . Sequence variants in which the CAACAG cas- 
sette is either deleted (Q 2 = 0), or duplicated (Q 2 = 4), have been 
reported (Table S1, appendix). In these cases, CAG length estimated 
by fragment length analysis may not equal the number of pure 
CAGs ( i.e. Q FL  = Q 1 ). The glutamine-encoding CAG/CAA tract is 
followed downstream by a proline-encoding CCA/CCG/CCT repeat 
tract, that although polymorphic ( Fig. 2 , Table 1 ), has no apparent 
impact on HD AAO [12] . 
In other repeat expansion disorders, variant repeat interrup- 
tions modify mutational dynamics and disease severity [1] . We hy- 
pothesised that CAG repeat sequence variants in HTT exon one, 
and DNA repair gene variants, may directly modify somatic expan- 
sion and consequent HD outcomes. Here, we sought to test these 
hypotheses by high-throughput ultra-deep DNA sequencing to re- 
veal allele structure and quantify somatic expansions in individuals 
carrying disease-associated HTT alleles and to correlate these data 
with HD clinical outcomes and DNA repair gene variants. 
2. Methods 
2.1. Study design and populations 
The aim of the study was to sequence the HTT CAG/CAA re- 
peat, quantify somatic expansions, genotype candidate DNA repair 
gene polymorphisms and correlate these data with HD clinical out- 
comes. As a discovery cohort, we selected 203 participants carry- 
ing disease-associated HTT alleles with from 40 to 50 CAG repeats 
with progression scores from TRACK-HD (105 premanifest, and 98 
manifest for motor symptoms) ( Table 2 ) (Supplementary methods 
in appendix). As a replication cohort, we selected 543 participants 
carrying disease-associated HTT alleles with from 40 to 50 CAG re- 
peats from Enroll-HD, of which 531 had all of the data available for 
genotype to phenotype analyses (141 premanifest, and 390 man- 
ifest for motor symptoms) ( Table 2 ) (Supplementary methods in 
appendix) [13] . 
2.2. Procedures 
Participants were recruited to TRACK-HD between 2008 and 
2011 [14] , and Enroll-HD from 2012 [13] . Clinical and genetic data 
were obtained from CHDI, and new genetic data generated, for 
TRACK-HD participants between October 2015 and October 2016, 
and Enroll-HD between June 2016 and December 2017. The pri- 
mary HD clinical outcomes we considered in our analyses were: 
motor AAO; Uniﬁed Huntington’s Disease Rating Scale (UHDRS) to- 
tal motor score (TMS) [15] ; UHDRS total functional capacity (TFC) 
[15] ; and TRACK-HD progression score (Supplementary methods in 
appendix) [14] . 
2.3. HTT exon one repeat region sequencing and genotyping 
The HTT exon one repeat region was ampliﬁed from 20 ng of 
blood DNA using MiSeq-compatible PCR primers, sequenced on 
MiSeq [16] and genotyped using ScaleHD (v0.251) (Supplemen- 
tary methods in appendix). The ratio of somatic CAG expansions (
numb er of soma tic expa nsion prod ucts 
numb er of prog enit or alle le prod ucts 
)
was quantiﬁed from the MiSeq 
read count distributions (see details in Supplementary methods in 
appendix). 
2.4. Selection of candidate SNPs and genotyping 
Full details of candidate SNP selection and genotyping are pro- 
vided in section I.1.9 of the appendix. 
2.5. Statistical analyses 
Statistical analyses were undertaken in R (v3.4.3) [17] using 
RStudio (version 1.0.153, see appendix for a full a list of R func- 
tions and packages used) [18] . All individuals are represented once 
in each analysis. Each data point represents a single baseline value 
for each participant except for three-year longitudinal data avail- 
able in TRACK-HD for TMS and TFC. These longitudinal TMS and 
TFC data were used to express the inﬂuence of Q 2 and the so- 
matic expansion score on the progression score in units of clin- 
ical measurements that are more commonly used ( i.e . TMS and 
TFC). To do so, participant-speciﬁc slopes derived from mixed ef- 
fect models with correlated random intercepts and slopes (with 
a ﬁxed ‘years of follow-up’ effect and a random ‘participant’ ef- 
fect) were used as participant-speciﬁc rate of change in TMS and 
TFC (TMSrate and TFCrate). Multiple linear regressions were per- 
formed to investigate the association of ‘CAG’ length (Q T or Q 1 ), 
number of additional glutamine codons (Q 2 ), and age, with the ra- 
tio of somatic CAG expansions (models SEQ T , SEQ 1 and SEQ 1 Q 2 ), 
and derive an age- and pure CAG (Q 1 )-corrected individual-speciﬁc 
somatic expansion score. Multivariate time-to-event analyses were 
carried out using stratiﬁed Cox proportional hazard regressions to 
investigate the association of ‘CAG’ length (Q T , Q 1 or Q FL ), num- 
ber of additional glutamine codons (Q 2 ) and the somatic expan- 
sion score with the time-to-onset of HD motor symptoms (mod- 
els AAOQ T , AAOQ 1 , AAOQ 1 Q 2 and AAOQ FL Q 2 ). For individuals with- 
out HD motor onset, the censored time was the age at the last 
TRACK-HD or Enroll-HD periodic dataset 3 visit. Cohort and sex 
were considered as strata in all Cox regressions. We conﬁrmed that 
the proportional hazard assumption could be assumed for each 
Cox regression model ﬁt and each covariate ( p > 0 ·106). To derive 
Please cite this article as: M. Ciosi, A. Maxwell and S.A. Cumming et al., A genetic association study of glutamine-encoding DNA sequence 
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Table 1 
Allele structures observed at the HTT exon one repeat locus. 
Allele structure code 
Q 1 -Q 2 -P 1 -P 2 -P 3 
DNA sequence Variant annotation 
(CAG) Q1 (CAACAG) Q2 (CCGCCA) P1 (CCG) P2 (CCT) P3 
Glutamines 
Total (Q 1 + Q 2 ) 
Prolines 
Total (P 1 + P 2 + P 3 ) 
Allele frequency (%) [ n individuals] 
TRACK-HD [203] Enroll-HD [543] 
Non-disease Disease Non-disease Disease 
Q 1 -2-2-P 2 -2 (CAG) Q1 (CAACAG) 1 (CCGCCA) 1 (CCG) P2 (CCT) 2 Q 
1 + 2 P 2 + 4 94 ·09 [191] 96 ·06 [195] 91 ·53 [497] 97 ·61 [530] 
LRG_763:c.52_153CAG[Q1]CAACAG[1]CCGCCA[1]CCG[P2]CCT[2] 
Q 1 -4-2-7-3 (CAG) Q1 (CAACAG) 2 (CCGCCA) 1 (CCG) 7 (CCT) 3 Q 
1 + 4 P 2 + 5 3 ·86 [8] 2 ·96 [6] 2 ·95 [16] 1 ·29 [7] 
LRG_763:c.52_153CAG[Q1]CAACAG[2]CCGCCA[1]CCG[7]CCT[3] 
17-2-0-6-2 (CAG) 17 (CAACAG) 1 (CCGCCA) 0 (CCG) 6 (CCT) 2 Q 
1 + 2 P 2 + 2 - - 0 ·18 [1] - 
LRG_763:c.52_153CAG[17]CAACAG[1]CCGCCA[0]CCG[6]CCT[2] 
Q 1 -2-0-9-2 (CAG) Q1 (CAACAG) 1 (CCGCCA) 0 (CCG) 9 (CCT) 2 Q 
1 + 2 P 2 + 2 1 ·48 [3] - 4 ·97 [27] - 
LRG_763:c.52_153CAG[Q1]CAACAG[1]CCGCCA[0]CCG[9]CCT[2] 
Q 1 -2-2-9-3 (CAG) Q1 (CAACAG) 1 (CCGCCA) 1 (CCG) 9 (CCT) 3 Q 
1 + 2 P 2 + 5 0 ·49 [1] - 0 ·18 [1] - 
LRG_763:c.52_153CAG[Q1]CAACAG[1]CCGCCA[1]CCG[9]CCT[3] 
Q 1 -0-2-7-2 (CAG) Q1 (CAACAG) 0 (CCGCCA) 1 (CCG) 7 (CCT) 2 Q 
1 P 2 + 4 - 0 ·49 [1] - 0 ·55 [3] 
LRG_763:c.52_153CAG[Q1]CAACAG[0]CCGCCA[1]CCG[7]CCT[2] 
20-0-2-11-2 (CAG) 20 (CAACAG) 0 (CCGCCA) 1 (CCG) 11 (CCT) 2 Q 
1 P 2 + 4 - - 0 ·18 [1] - 
LRG_763:c.52_153CAG[20]CAACAG[0]CCGCCA[1]CCG[11]CCT[2] 
41-0-0-9-2 (CAG) 41 (CAACAG) 0 (CCGCCA) 0 (CCG) 9 (CCT) 2 Q 
1 P 2 + 2 - 0 ·49 [1] - - 
LRG_763:c.52_153CAG[41]CAACAG[0]CCGCCA[0]CCG[9]CCT[2] 
Q 1 -0-0-11-2 (CAG) Q1 (CAACAG) 0 (CCGCCA) 0 (CCG) 11 (CCT) 2 Q 
1 P 2 + 2 - - - 0 ·37 [2] 
LRG_763:c.52_153CAG[Q1]CAACAG[0]CCGCCA[0]CCG[11]CCT[2] 
41-3-2-7-2 (CAG) 41 (CAA) 1 (CAACAG) 1 (CCGCCA) 1 (CCG) 7 (CCT) 2 Q 
1 + 3 P 2 + 4 - - - 0 ·18 [1] 
LRG_763:c.52_153CAG[41]CAA[1]CAACAG[1]CCGCCA[1]CCG[7]CCT[2] 
See Fig. 2 for further details of allele structures. Q 1 = number of pure CAGs; Q 2 = the number of downstream glutamine-encoding CAA/CAG repeats; P 1 = number of CCG/CCA proline codons upstream of the pure CCG repeat 
tract; P 2 = number of pure CCGs; P 3 = number of CCT repeats. Disease-associated alleles with either zero, three or four downstream glutamine codons (Q 2 = 0, 3 or 4), are indicated with a red upward triangle, green diamond, 
or green downward triangle, respectively. The variant annotation describes the HTT exon one sequence variants using the Sequence Variant Nomenclature of the Human Genome Variation Society based on the HTT Locus 
Reference Genomic sequence LRG_763. 
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Table 2 
Participant characteristics . Participants excluded from the data analyses are not included. 
Characteristics TRACK-HD Enroll-HD TRACK-HD and Enroll-HD 
Number of individuals 203 531 734 
Range of age at DNA sampling (years) 18 ·63 to 64 ·13 18 ·42 to 75 ·50 18 ·42 to 75 ·50 
Mean age at DNA sampling (years (SD)) 45 ·00 (9 ·93) 48 ·84 (12 ·25) 47 ·78 (11 ·77) 
Range of age at baseline (years) 18 ·63 to 64 ·13 18 ·42 to 75 ·50 18 ·42 to 75 ·50 
Mean age at baseline (years (SD)) 44 ·96 (9 ·90) 48 ·84 (12 ·25) 47 ·77 (11 ·77) 
Sex = female (%) 54 ·68 53 ·67 53 ·95 
Manifest for Huntington disease motor symptoms 48 ·28% 73 ·45% 66 ·49% 
Mean age at onset of motor symptoms (years (SD)) 45 ·27 (8 ·89) 45 ·85 (10 ·72) 45 ·73 (10 ·37) 
Mean total motor score at baseline (SD) 12 ·06 (12 ·64) 23 ·58 (20 ·40) 20 ·40 (19 ·27) 
Mean total functional capacity at baseline (SD) 11 ·93 (1 ·73) NA NA 
Mean pure CAG (Q 1 ) in the disease-associated allele (SD) 43 ·14 (2 ·16) 43 ·25 (2 ·40) 43 ·22 (2 ·33) 
Mean total encoded glutamine (Q T ) in the disease-associated allele (SD) 45 ·18 (2 ·25) 45 ·26 (2 ·42) 45 ·24 (2 ·37) 
Mean fragment length estimate of CAG (Q FL ) in the disease-associated allele (SD) 43 ·15 (2 ·21) 43 ·25 (2 ·42) 43 ·22 (2 ·36) 
relative effect sizes, adjusted survival curves and median time to 
HD motor onset for the different numbers of additional glutamine 
codon categories (Q 2 ), and positive and negative somatic expan- 
sion scores, were estimated based on the mean values of the other 
covariates. Multiple linear regressions were performed to investi- 
gate the association of ‘CAG’ length (Q T , Q 1 or Q FL ), number of 
additional glutamine codons (Q 2 ), age and the somatic expansion 
score with the progression score (models ProgQ 1 and ProgQ FL ), 
TMSrate (model TMSrateQ 1 Q 2 ), TFCrate (model TFCrateQ 1 Q 2 ) and 
baseline TMS (models TMSQ T , TMSQ 1 , TMSQ 1 Q 2 and TMSQ FL Q 2 ). 
In the Cox and linear regression analyses, all continuous explana- 
tory variables (Q T , Q 1 , Q FL , age, baseline TMS, and baseline TFC) 
were centred, except for the somatic expansion score, which, as a 
regression residual was effectively already quasi-centred. We com- 
pared the goodness of ﬁt of regression models containing the same 
degrees of freedom ( i.e. regression with Q T vs regression including 
Q 1 ) via nonparametric bootstrapping of the r 2 (for multiple linear 
regressions) or the log-likelihood (for Cox proportional hazard re- 
gressions) statistic. We performed 50 0 0 bootstrap replications and 
estimated the conﬁdence interval via the bias-corrected acceler- 
ated (BCA) method [19,20] . ANOVA was used to compare regres- 
sion models containing, or not containing, the number of addi- 
tional encoded-glutamines (Q 2 ) as a covariate (model SEQ 1 com- 
pared to SEQ 1 Q 2 , model AAOQ 1 compared to AAOQ 1 Q 2 , and model 
TMSQ 1 compared to TMSQ 1 Q 2 ). For each comparison, the p -value 
associated with the ANOVA test-statistic ( F for linear regressions 
and χ2 for Cox regressions) was then estimated based on 10 5 per- 
mutations of the number of additional encoded-glutamines (Q 2 ). 
In order to avoid potential biases in p -value estimates due to small 
sample sizes for some levels of the number of additional glutamine 
codons (Q 2 ), for all linear and Cox regressions containing the num- 
ber of additional glutamine codons (Q 2 ) as a covariate ( i.e. SEQ 1 Q 2 , 
AAOQ 1 Q 2 , AAOQ FL Q 2 , ProgQ 1 , ProgQ FL , TMSrateQ 1 Q 2 , TFCrateQ 1 Q 2 , 
TMSQ 1 Q 2 , TMSQ FL Q 2 ), all the Q 2 -associated p -values were esti- 
mated based on the t- (for the linear regressions) or z -statistic (for 
the Cox regressions) using 10 5 permutations of the number of ad- 
ditional glutamine codons (Q 2 ). The effect size for each number 
of additional glutamine codons (Q 2 ) genotype on the progression 
score, TMSrate, TFCrate, and baseline TMS, was derived from the 
least-square means ( i.e. the means for each number of additional 
glutamine codons (Q 2 ) genotype adjusted for all other variables 
in the linear regression). All statistical analyses were two-sided 
and included sex, cohort and age at baseline (when appropriate) 
as covariates. Participants with missing data were excluded from 
relevant analyses ( Fig. 1 ). PLINK (v1.07) [21] and gPLINK (version 
2.050; http://zzz.bwh.harvard.edu/plink/gplink.shtml ) were used to 
test for Hardy-Weinberg equilibrium and the association between 
SNPs and somatic expansion score by linear regression with sex as 
a covariate. Meta-analyses of the association between SNPs and so- 
matic expansion score were performed using sample size-weighted 
analysis (based on p -values) in METAL [22] . Within each set of 
analyses (AAO, progression score, rate of change of TMS and TFC, 
baseline TMS, SNP association), the Benjamini-Hochberg false dis- 
covery rate (FDR) procedure was used to correct for multiple test- 
ing [23] . 
3. Results 
We analysed data from 203 participants from a TRACK-HD dis- 
covery cohort and 543 from an Enroll-HD replication cohort ( Fig. 
1 , Table 2 ). DNA sequencing revealed that > 95% of HTT alleles 
comprised the typical glutamine-encoding repeat structure where 
there was a single copy of the CAACAG cassette (Q 2 = 2) ( Fig. 2 , 
Table 1 ). We also detected three atypical glutamine-encoding re- 
peat structures with either duplication (Q 2 = 4, n = 13), or deletion 
(Q 2 = 0, n = 7), of the glutamine-encoding CAACAG cassette, or an 
additional CAA between the pure CAG tract and the CAACAG cas- 
sette (Q 2 = 3, n = 1) on the disease-associated chromosome ( Fig. 2 , 
Table 1 ). As expected, alleles with deletion of the CAACAG cas- 
sette (Q 2 = 0, n = 7) yielded fragment length CAG estimates (Q FL ) 
two repeats shorter than the pure CAG number (Q 1 ). Surprisingly, 
all the disease-associated alleles with duplication of the CAACAG 
cassette (Q 2 = 4, n = 13) yielded fragment length estimates (Q FL ) 
only one repeat longer than the pure CAG (Q 1 ), rather than the 
expected two (Figure S1A, appendix). These discrepancies presum- 
ably reﬂect mispriming of the PCR primer used for fragment length 
analysis that binds across the polymorphic region between the 
CAG and CCG tracts, yielding artefactual fragment length estimates 
(Q FL ) that have no direct biological correlate ( i.e. when Q 2 = 4, 
Q 1  = Q FL  = Q T − 2) (Figure S1B–F, appendix). 
Although somatic expansions in HD patient brain tissue may be 
very large [4] , the level of somatic mosaicism in peripheral tissues 
is low, but allele length-dependent and expansion-biased [7,8,24] . 
Here, sequencing of single input molecules of DNA revealed high 
levels of smaller PCR slippage products, but only a low proportion 
of products larger than the progenitor molecule (Figures S2 and 
S3, appendix). These data suggest the vast majority of expansion 
products detected in bulk DNA analyses of disease-associated alle- 
les represent genuine somatic expansions (Figure S3C, appendix). 
The ratio of somatic expansions 
(
numb er of soma tic expa nsion prod ucts 
numb er of prog enit or alle le prod ucts 
)
represents a quantitative measure of the degree of somatic expan- 
sion present in the blood DNA of an individual at a given point. 
Given the stabilising effects of repeat interruptions in other disor- 
ders [1] , it was not surprising that the ratio of somatic expansions 
was best predicted by an interaction between age at sampling and 
the length of the pure CAG repeat (Q 1 ), rather than the total 
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Fig. 1. Study design and sample exclusions. 
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Fig. 2. Allelic variation at the HTT exon one repeat locus . The schematic diagram shows the typical reference allele structure of the CAG/CCG repeat region in exon one 
of HTT (top). We here deﬁne the number of pure CAGs as Q 1 and the number of additional downstream glutamine-encoding CAA/CAG repeats as Q 2 . Thus, total encoded- 
glutamine Q T = Q 1 + Q 2 . We here deﬁne the number of copies of the proline codons before the pure CCG repeat as P 1 , the number of pure CCGs as P 2 , and the number of 
copies of the CCT proline codons as P 3 . Thus, total encoded-proline P T = P 1 + P 2 + P 3 . The ﬁgure shows schematic representations of the atypical alleles observed. Repeat 
codons are depicted: CAG glutamine codons as red boxes; CAA glutamine codons as green boxes; CCG proline codons as blue boxes; CCA proline codons as yellow boxes; 
and CCT proline codons as pink boxes. Disease-associated alleles with either zero, three or four downstream glutamine codons (Q 2 = 0, 3 or 4), are indicated with a red 
upward triangle, green diamond, or green downward triangle, respectively. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the 
web version of this article.) 
encoded-glutamine length (Q T ) (model SEQ T r 2 QT = 0 ·822, 
p < 2 ×10 −16 , model SEQ 1 r 2 Q1 = 0 ·836, p < 2 ×10 
−16 , Table 
S2, appendix, Fig. 3 A) (difference in r 2 = 0 ·014 (95% CI = 0 ·005 
to 0 ·025)). Once corrected for pure CAG (Q 1 ), the number of 
additional CAA/CAG codons (Q 2 ) had no impact on the ratio of 
somatic expansions in blood DNA (model SEQ 1 Q 2 pFDR Q2 = 0 = 0 ·36, 
pFDR Q2 = 4 = 0 ·36, p FDR Q2 = 0 ∗Age = 0 ·12, pFDR Q2 = 4 ∗Age = 0 ·51, Table 
S2, appendix) (permutation test for difference between models 
SEQ 1 Q 2 and model SEQ 1 , p = 0 ·10). The ratio of somatic expansions 
corrected for age at sampling, the number of pure CAG repeats 
(Q 1 ), sex and cohort (model SEQ 1 ) represents an individual-speciﬁc 
somatic expansion score. 
Motor AAO in HD is strongly predicted by the number of 
‘CAG’ repeats inherited as estimated by PCR fragment length anal- 
ysis (Q FL ) [25] . However, the existence of atypical CAG/CAA struc- 
tures allows us to ask whether HD clinical outcomes are best 
predicted by the length of the longest pure CAG tract (Q 1 ), or 
by the total number of consecutive glutamines encoded by the 
CAG/CAA repeat (Q T ). In addition, the availability of individual- 
speciﬁc somatic expansion scores, allows us to assess whether 
somatic expansions in blood are associated with variation in 
AAO. We thus performed multivariate time-to-event Cox propor- 
tional hazard regression analyses of variation in AAO (time to 
HD onset) dependent on ‘CAG’ length (pure CAG (Q 1 ) or total 
encoded-glutamine length (Q T )), and the somatic expansion score. 
Pure CAG length (Q 1 ) was a better predictor of AAO than to- 
tal encoded-glutamine (Q T )(model AAOQ T log-likelihood = −1899, 
model AAOQ 1 log-likelihood = −1884, 95% CI of log-likelihood dif- 
ference: 5 ·05 to 30 ·93, Table S3, appendix). 
Although pure CAG length (Q 1 ) was a better predictor of AAO 
than total encoded glutamine length (Q T ), under the assumption 
that the actual toxic element in cells is the polyglutamine pro- 
tein [9] , we might still expect that after correcting for the num- 
ber of pure CAG repeats (Q 1 ), fewer glutamine-encoding CAA/CAG 
codons (Q 2 ) would increase AAO (Figure S4, appendix). Surpris- 
ingly, rather than increasing AAO relative to typical allele carri- 
ers (Q 2 = 2), after correcting for pure CAG length (Q 1 ), absence of 
the CAACAG cassette (Q 2 = 0, n = 7) was associated with an earlier 
AAO of ∼10 years with a median age at HD onset = 38 years (95% 
CI = 34 to 45) relative to 48 years (95% CI = 46 to 49) for typical 
alleles (Q 2 = 2) ( pFDR Q2 = 0 = 7 ·3 ×10 
−4 , model AAOQ 1 Q 2 , Table S3, 
appendix) ( Fig. 4 A). After correcting for pure CAG length, dupli- 
cation of the CAACAG cassette (Q 2 = 4, n = 13) was not associated 
with an earlier AAO with a median time to HD onset = 48 years 
(95% CI = 45 to 54) ( pFDR Q2 = 4 = 0 ·95, model AAOQ 
1 Q 2 , Table S3, 
appendix) ( Fig. 4 A). 
The number of additional glutamine codons (Q 2 ) was not as- 
sociated with the length of the pure CAG tract (Q 1 ) ( r 2 = 0 ·001, 
p = 0 ·17) (Figure S5, appendix). However, over the pure CAG (Q 1 ) 
range of 40 to 50 repeats, there was a positive association between 
the number of additional glutamine codons (Q 2 ) and the length 
of the total glutamine-encoding CAA/CAG repeat (Q T ) ( r 2 = 0 ·034, 
p = 2 ×10 −7 ) (Figure S5, appendix). Some association was in- 
evitable because the total glutamine length (Q T ) is sum of the 
number of pure CAGs (Q 1 ) and the number of additional glu- 
tamine codons (Q 2 ) ( i.e. Q T = Q 1 + Q 2 ). Furthermore, the pure 
CAG length selection criteria (40 ≤ Q 1 ≤ 50) differentially elimi- 
nates some genotypes at either end of the distribution: individu- 
als with Q T = 40 and Q 2 = 0 (and therefore Q 1 = 40) were included, 
but individuals with Q T = 40, and Q 2 = 2 (and therefore Q 1 = 38) 
were excluded; likewise, individuals with Q T = 53, and Q 2 = 4 (and 
therefore Q 1 = 49) were included, but individuals with Q T = 53 
and Q 2 = 2 (and therefore Q 1 = 51) were excluded. This associa- 
tion might also have been compounded by an ascertainment bias 
whereby individuals with absence of the CAACAG cassette (Q 2 = 0) 
may have an increased probability of receiving a diagnosis with a 
smaller total encoded glutamine repeat length (Q T ). 
In order to gauge the level of prognostic inaccuracy with the 
standard test, we revealed that relative to that predicted by frag- 
ment length analyses (Q FL ) alone, absence of the CAACAG cassette 
(Q 2 = 0, n = 7) was associated with an error in the predicted AAO of 
∼16 years with a median age at HD onset = 32 years (95% CI = 29 
to 39) relative to 48 years (95% CI = 46 to 49) for typical alle- 
les (Q 2 = 2) ( pFDR Q2 = 0 < 1 ·5 ×10 
−5 , model AAOQ FL Q 2 , Table S3, 
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Fig. 3. Somatic expansion in Huntington disease. A) The ratio of somatic expansions of the HTT exon one CAG repeat is allele length and age-dependent. The graph shows 
the ratio of somatic expansions 
(
number of somatic expansion products 
number of progenitor allele products 
)
in blood DNA plotted against the age at sampling for 746 participants in the TRACK-HD and Enroll-HD cohorts. 
Each point is colour coded with respect to the length of the inherited progenitor allele length (Q 1 ). The scatterplot also shows the sex- and cohort-adjusted ﬁtted regression 
lines for each pure CAG repeat length (Q 1 ) derived from model SEQ 1 which includes an interaction between age at sampling and pure CAG repeat length (Q 1 ) (Table S2, 
appendix). B) Somatic expansion scores in blood DNA predict age at onset in Huntington disease. The graph shows adjusted time to event curves from a Cox proportional 
hazard model of HD motor onset according to the sign of the pure CAG somatic expansion score (determined using model SEQ 1 , Table S2, appendix). The solid lines represent 
the age-dependent probability of HD motor onset: orange for participants with positive expansion scores; and green for participants with negative expansion scores. The light 
shaded regions represent the 95% CI for the onset probability curves. A vertical tick mark on the curves indicates that a participant was censored at this time. Vertical dashed 
lines indicate median survival for each somatic expansion score category: individuals with a positive blood DNA somatic expansion score had a median age at onset = 46 
years (95% CI 45 to 48); whilst individuals with a negative blood DNA somatic expansion score had a median age at onset = 49 years (95% CI 47 to 50). (For interpretation 
of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.) 
appendix) ( Fig. 4 B). Conversely, duplication of the CAACAG cas- 
sette (Q 2 = 4, n = 13) appeared to be associated with an ∼3-year 
later predicted AAO with a median time to HD onset = 51 years 
(95% CI = 48 to 59) ( pFDR Q2 = 4 = 0 ·11, model AAOQ 
FL Q 2 , Table S3, 
appendix) ( Fig. 4 B). 
If the accumulation of somatic expansions contributes to- 
ward disease development, then individual-speciﬁc variation in 
the rate of somatic expansion should be associated with vari- 
ation in HD outcomes. As hypothesised, variation in AAO, cor- 
rected for the number of pure CAG repeats (Q 1 ), was correlated 
with the individual-speciﬁc somatic expansion scores in blood 
DNA (model AAOQ 1 Q 2 , hazard ratio = 3 ·05, 95% CI = 1 ·94 to 4 ·80, 
pFDR SE = 2 ·8 ×10 
−6 ). Individuals with a positive blood DNA somatic 
expansion score (median age at onset = 46, 95% CI 45 to 48) had 
a three year earlier median age at onset than individuals with a 
negative blood DNA somatic expansion score (median age at on- 
set = 49, 95% CI 47 to 50) ( Fig. 3 B) i.e. individuals with more so- 
matic expansions in blood DNA than average, had an earlier age at 
onset than average. 
Although AAO is of particular interest to patients, it can be diffi- 
cult to assess, and it is unlikely to be a clinical trial outcome in the 
near term. However, careful clinical testing and imaging can reveal 
differences in the premanifest HD population many years before 
the onset of overt motor symptoms [2,26,27] . The TRACK-HD study 
was established speciﬁcally to determine the utility of multiple 
outcomes to assess disease progression in the late premanifest and 
early HD population as representative of likely trial cohorts. Pre- 
viously, Hensman Moss et al., used principal component analysis 
to combine 24 clinical variables, encompassing brain volume, cog- 
nition and motor performance, corrected for age and ‘CAG’ repeat 
length (Q FL ) to derive a progression score in TRACK-HD (appendix) 
[14] . This progression score also proved very sensitive for detect- 
ing genetic modiﬁers of HD [14] . Here, the two individuals with 
deletion of the CAACAG cassette (Q 2 = 0) in their disease-associated 
allele ranked as the two fastest progressing TRACK-HD partici- 
pants using the previously determined progression score based on 
their measured ‘CAG’ length (Q FL ) ( Fig. 4 C). Conversely, 5/6 carri- 
ers of the CAACAG cassette duplication (Q 2 = 4) had a lower dis- 
ease progression score than average ( Fig. 4 C). Regression analysis 
conﬁrmed that relative to that predicted by the fragment length 
estimate of CAG (Q FL ), absence of the CAACAG cassette (Q 2 = 0, 
n = 2) was associated with a 3 ·1 unit (95% CI = 1 ·8 to 4 ·4) increase 
in the progression score ( pFDR Q2 = 0 = 1 ×10 
−4 ); and duplication of 
the CAACAG cassette (Q 2 = 4, n = 6) was associated with an appar- 
ent −0 ·99 unit (95% CI = −1 ·76 to −0 ·22) decrease in the progres- 
sion score ( pFDR Q2 = 4 = 0 ·028) ( Fig. 4 D, model ProgQ 
FL , Table S4, 
appendix). When the disease progression score was re-calculated 
using the length of the pure CAG repeat (Q 1 ), the protective ef- 
fect of the number of additional glutamine codons (Q 2 ) was re- 
duced, but remained apparent: absence of the CAACAG cassette 
(Q 2 = 0, n = 2) was associated with a 2 ·2 unit (95% CI = 0 ·9 to 3 ·6, 
pFDR Q2 = 0 = 0 ·014) increase in the progression score; and duplica- 
tion of the CAACAG cassette (Q 2 = 4, n = 6) was nominally associ- 
ated with a −0 ·74 unit (95% CI = −1 ·54 to 0 ·05, pFDR Q2 = 4 = 0 ·110) 
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Fig. 4. Associations between HTT exon one CAG repeat structures and HD clinical outcomes and biases associated with the prediction of HD clinical outcomes based on 
fragment length estimates of CAG . The adjusted probability curves of age at HD motor onset ( A/B ) show the probability of motor onset predicted on the basis of the pure 
CAG length (Q 1 , A ) or the fragment length estimate of CAG (Q FL , B ) for each number of additional glutamine codons genotype (Q 2 = 0, red; Q 2 = 2, black; Q 2 = 4, green). The 
light shaded regions represent the 95% CI for the onset probability curves. A vertical tick mark on the curves indicate that a participant was censored at this time. Vertical 
dashed lines indicate median survival for each Q 2 genotype. For the pure CAG (Q 1 ) estimates ( A ): individuals Q 2 = 0 had a median age at onset = 38 years (95% CI = 34 to 
45); individuals Q 2 = 2 had a median age at onset = 48 years (95% CI = 46 to 49); and individuals Q 2 = 4 had a median age at onset = 48 years (95% CI = 45 to 54). For the 
CAG fragment length (Q FL ) estimates ( B ): individuals Q 2 = 0 had a median age at onset = 32 years (95% CI = 29 to 39); individuals Q 2 = 2 had a median age at onset = 48 
years (95% CI = 46 to 49); and individuals Q 2 = 4 had a median age at onset = 51 years (95% CI = 48 to 59). The scatterplots ( C/E ) and the whisker plots ( D/F ) show the 
ranked TRACK-HD progression score predicted on the basis of the fragment length estimate of CAG (Q FL , C/D ) or pure CAG (Q 1 , E/F ) dependent on the number of additional 
glutamine codons (Q 2 ). The progression scores are normally distributed around zero, with zero representing the population average disease progression. Negative values 
represent individuals with slower than average disease progression and positive values represent individuals with faster than average disease progression. The whisker plots 
show the mean (diamond) and 95% CI (whiskers) on the basis of the fragment length estimate of CAG (Q FL , E ) or pure CAG length (Q 1 , F ) dependent on the number of 
additional glutamine codons (Q 2 = 0, red; Q 2 = 2, black; Q 2 = 4, green). The whisker plots ( G/H/I/J ) show the least-square means for the rate of change of TMS (TMS rate, G ) 
and TFC (TFC rate , H ) predicted on the basis of the pure CAG length (Q 1 ), and TMS predicted on the basis of the pure CAG (Q 1 , G ) or fragment length estimate of CAG (Q FL , 
H ) for each number of additional glutamine codons (Q 2 ) genotype ( i.e. the means associated with each number of additional glutamine codons (Q 2 ) genotype adjusted for 
all other variables in the linear regression). 
decrease in the progression score ( Fig. 4 E/F, model ProgQ 1 , Table 
S4, appendix). Individuals with higher somatic expansion scores 
were also revealed as having higher TRACK-HD progression scores: 
a one-unit increase in the blood DNA somatic expansion score was 
associated with a 0 ·98 unit increase in the pure CAG (Q 1 ) progres- 
sion score (95% CI = 0 ·24 to 1 ·72, pFDR SEQ1 = 0 ·028, model ProgQ 
1 , 
Table S4, appendix). 
Sensitive as the TRACK-HD progression score is as a detector 
of genetic modiﬁers, it is hard to relate to individual features of 
the disease. Thus, in order to increase the interpretability of the 
overall effects on progression, we determined the effect sizes of 
the sequence of the CAG/CAA repeat and the somatic expansion 
score on the rate of change of total motor score (TMS) and the 
total functional capacity (TFC) score. TMS and TFC score are com- 
ponents of the TRACK-HD progression score that are widely used, 
sensitive clinical outcome measures of HD (note that a higher TMS, 
and a lower TFC, is a worse outcome) [15] . These analyses revealed 
that after correcting for baseline TMS, age and the length of the 
pure CAG tract (Q 1 ), absence of the CAACAG cassette (Q 2 = 0, n = 2) 
was nominally associated with a faster rate of increase of TMS 
of ∼1 units year −1 (95% CI = −0 ·9 to 2 ·8, pFDR Q2 = 0 = 0.328) and a 
faster rate of decrease of TFC of ∼-0 ·8 units year −1 (95% CI = −1 ·5 
to −0 ·2, pFDR Q2 = 0 = 0.038), whilst presence of the CAACAG du- 
plication (Q 2 = 4, n = 6) appeared to be associated with a slower 
rate of increase in TMS of ∼-0 ·3 units year −1 (95% CI = −1 ·4 to 
0 ·9, pFDR Q2 = 4 = 0 ·66) and a slower rate of decrease in TFC of 
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Table 3 
Genetic modiﬁers of blood DNA somatic expansion scores of the HTT CAG repeat. Shown is the genetic association data for the six SNPs genotyped in TRACK-HD and 
replicated in Enroll-HD. Additional details of all the SNPs analysed are provided in Table S7 (appendix). SNPs are ordered by decreasing p -value of their association with 
the somatic expansion score in the TRACK-HD cohort. Chr: chromosome. A1: minor allele. β: regression coefficient. p : unadjusted p -value. p FDR: p -value adjusted for 
multiple testing using the Benjamini-Hochberg false discovery rate correction. ∗Note that in a preliminary analysis using a slightly larger TRACK-HD cohort including four 
participants with 39 pure CAG repeats (Q 1 = 39) and six non-Caucasians, the association between somatic expansion score and rs20579 in LIG1 was p = 0 ·072, and rs20579 
was thus selected for replication in Enroll-HD. 
SNP ID Chr Gene A1 A2 TRACK-HD Enroll-HD Meta-analysis 
β p p FDR β p p FDR p FDR 
rs3512 15 FAN1 C G 0 ·060 0 ·003 0 ·034 0 ·050 6 ·7 ×10 −5 4 ·0 × 10 −4 4 ·8 × 10 −6 
rs175080 14 MLH3 A G −0 ·053 0 ·004 0 ·034 −0 ·029 0 ·013 0 ·026 8 ·0 ×10 −4 
rs147804330 2 RP11-481J13.1 A G −0 ·107 0 ·010 0 ·073 0 ·003 0 ·912 0 ·912 0 ·246 
rs1382539 5 MSH3 A G −0 ·045 0 ·018 0 ·101 −0 ·023 0 ·077 0 ·116 0 ·009 
rs1799977 3 MLH1 G A −0 ·032 0 ·093 0 ·314 −0 ·034 0 ·009 0 ·026 0 ·004 
rs20579 19 LIG1 A G −0 ·042 0 ·112 ∗ 0 ·314 −0 ·002 0 ·908 0 ·912 0 ·351 
∼0 ·1 units year −1 (95% CI = −0 ·2 to 0 ·5, pFDR Q2 = 4 = 0 ·53) (Ta- 
ble S5, models TMSrateQ 1 Q 2 and TFCrateQ 1 Q 2 , appendix) ( Fig. 
4 G/H). A one-unit increase in the blood DNA somatic expan- 
sion score was nominally associated with a 1 ·7 unit year −1 (95% 
CI = 0 ·7 to 2 ·8, pFDR SEQ1 = 0 ·002) acceleration in the rate of in- 
crease of TMS and with a −0 ·12 unit year −1 (95% CI = −0 ·46 to 
0 ·23, pFDR SEQ1 = 0 ·561) acceleration in the rate of decrease of TFC 
(Table S5, models TMSrateQ 1 Q 2 and TFCrateQ 1 Q 2 , appendix). 
TMS was also available for Enroll-HD, thus in order to assess 
the generalisability of the TRACK-HD data, we also determined if 
baseline TMS was associated with the sequence of the CAG/CAA 
repeat and the somatic expansion score. In the combined co- 
horts, pure CAG length (Q 1 ) was a better predictor of age-adjusted 
baseline TMS than total encoded-glutamine (Q T ) (model TMSQ T 
r 2 = 0 ·558, model TMSQ 1 r 2 = 0 ·578, Table S6, appendix) (differ- 
ence in r 2 = 0 ·020 (95% CI = 0 ·0098 to 0 ·036)). Higher TMS is a 
worse outcome and these analyses revealed that after correcting 
the age-adjusted TMS for pure CAG (Q 1 ), absence of the CAACAG 
cassette (Q 2 = 0, n = 7) was associated with an increase in base- 
line TMS of ∼2 ·3 units with a mean baseline TMS = 6 ·2 units (95% 
CI = 5 ·1 to 7 ·4) relative to 3 ·9 units (95% CI = 3 ·8 to 4 ·1) for typ- 
ical alleles (Q 2 = 2) ( pFDR Q2 = 0 = 1 ·9 ×10 
−4 , model TMSQ 1 Q 2 , Table 
S6, appendix) ( Fig. 4 I). Duplication of the CAACAG cassette (Q 2 = 4, 
n = 13) was not associated with a lower TMS = 3 ·9 units (95% 
CI = 3 ·1 to 4 ·7) (p FDR Q2 = 4 = 0 ·92, model TMSQ 
1 Q 2 , Table S6, ap- 
pendix) ( Fig. 4 I). If instead, the age-adjusted TMS was corrected for 
the fragment length estimate of CAG (Q FL ), absence of the CAACAG 
cassette (Q 2 = 0, n = 7) was associated with an increase in base- 
line TMS of ∼3 ·7 units with a mean baseline TMS = 7 ·6 units (95% 
CI = 6 ·5 to 8 ·8) relative to 3 ·9 units (95% CI = 3 ·8 to 4 ·1) for typi- 
cal alleles (Q 2 = 2) ( pFDR Q2 = 0 = 1 ·9 ×10 
−5 , model TMSQ FL Q 2 , Table 
S6, appendix) ( Fig. 4 J). Duplication of the CAACAG cassette (Q 2 = 4, 
n = 13) appeared to be associated with a 0 ·8 unit lower TMS with a 
mean TMS = 3 ·1 years (95% CI = 2 ·3 to 4 ·0) ( pFDR Q2 = 4 = 0 ·08, model 
TMSQ FL Q 2 , Table S6, appendix) ( Fig. 4 J). Individuals with higher so- 
matic expansion scores were also revealed as having higher TMS 
( pFDR SEQ1 = 2 ·5 ×10 
−4 , model TMSQ 1 Q 2 , Table S6, appendix). 
To determine whether DNA repair gene variants found to 
modify HD outcomes [10,14] might act by modifying somatic 
expansion, we genotyped 28 candidate SNPs in the discov- 
ery TRACK-HD cohort ( Table 3 , Table S7, appendix). Although 
ﬁve SNPs were nominally signiﬁcantly ( p < 0 ·05) associated 
with the somatic expansion scores, only three SNPs at the 
MLH3 and MTMR10/FAN1 loci remained signiﬁcant after cor- 
rection for multiple testing ( pFDR rs175080 = 0 ·034 in MLH3 , and 
pFDR rs2140734 and pFDR rs3512 = 0 ·034 at the MTMR10/FAN1 lo- 
cus, Table 3 , Table S7, appendix). To replicate these effects in 
Enroll-HD, we selected six candidate SNPs that approached sta- 
tistical signiﬁcance in the TRACK-HD cohort ( p < ∼0 ·1) and 
that could be genotyped using KASP assays. We revealed as- 
sociations with somatic expansion scores for variants in MLH3 
( pFDR rs175080 = 0 ·026), FAN1 ( pFDR rs3512 = 4 ·0 ×10 
−4 ) and MLH1 
( pFDR rs1799977 = 0 ·026) in the Enroll-HD cohort ( Table 3 ). Signals 
for MLH3 ( pFDR rs175080 = 8 ·0 ×10 
−4 ), FAN1 ( pFDR rs3512 = 4 ·8 ×10 
−6 ) 
and MLH1 ( pFDR rs1799977 = 0 ·004) were further ampliﬁed in a 
meta-analysis of the TRACK-HD and Enroll-HD association tests, 
which also brought a variant in MSH3 below the nominal multi- 
ple testing signiﬁcance threshold ( pFDR rs1382539 = 0 ·009, Table 3 , 
Table S7, appendix). 
4. Discussion 
We used high-throughput ultra-deep sequencing to determine 
the precise structure of the HTT exon one HD-causing repeat, and 
simultaneously quantify somatic expansions, in two large cohorts 
of carriers of HD-associated alleles. We established that, although 
none of the DNA sequence variants detected changed the amino 
acid sequence of the encoded polyglutamine repeat (beyond its 
length), the precise DNA sequence of the HTT polyglutamine- 
encoding repeat was associated with HD outcomes. Notably, HD 
clinical outcomes were best predicted by the number of pure 
CAG repeats (Q 1 ) rather than the total number of consecutive 
glutamine-encoding CAG/CAA repeats (Q T ) on the disease chro- 
mosome. The ﬁnding that duplication of the CAACAG cassette 
(Q 2 = 4) appeared to be associated with a later AAO compared 
to that predicted using standard fragment length analysis (Q FL ) 
is consistent with previous reports of a protective HTT haplotype 
present in a subset of Danish HD families [28] . Although not 
originally considered as a likely explanation, the protective HD 
haplotype was revealed to carry the duplication of the CAACAG 
cassette (Q 2 = 4) [28] on a (CCGCCA) 1 (CCG) 7 (CCT) 3 repeat haplo- 
type [29] , identical to all 37 CAACAG cassette duplication alleles 
we detected ( Table 1 ) and in three previous reports (Table S1, 
appendix). The effects of absence or duplication of the CAACAG 
cassette with predicted age at onset have also been replicated in 
two very recent reports published while this paper was in review 
[ 30 , 31 ]. In the largest GWAS of modiﬁers of HD age at motor onset 
yet reported, the Genetic Modiﬁers of HD team identiﬁed a rare 
protective HTT haplotype, which, based on the fragment length 
estimate of ‘CAG’ (Q FL ), delayed motor onset by ∼ 4 to 5 years and 
was associated with the CAACAG cassette duplication (Q 2 = 4) and 
(CCGCCA) 1 (CCG) 7 (CCT) 3 repeat haplotype [30] . Wright et al., also 
associated the CAACAG cassette duplication (Q 2 = 4) with delayed 
motor onset of ∼ 4 years based on the fragment length estimate of 
‘CAG’ (Q FL ) [31] . The Genetic Modiﬁers of HD team also detected 
an even rarer deleterious HTT haplotype, which, based on the 
fragment length estimate of ‘CAG’, accelerated motor onset by ∼ 9 
to 10 years, and was associated with loss of the CAACAG cassette 
(Q 2 = 0) and a (CCGCCA) 0 (CCG) 12 (CCT) 2 repeat haplotype [30] . 
Similarly, Wright et al., associated the CAACAG cassette deletion 
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(Q 2 = 0) with an accelerated age at onset of ∼29 years in carriers 
of reduced penetrance alleles (36 to 39 ‘CAG’ repeats), and ∼ 13 
years in carriers of full mutations (40 to 50 ‘CAG’ repeats), relative 
to the age at onset predicted by the fragment length estimate 
of ‘CAG’ (Q FL ) [31] . Interestingly, Wright et al., observed the loss 
of the CAACAG cassette (Q 2 = 0) on either a (CCGCCA) 0 (CCG) 10 , 
(CCGCCA) 0 (CCG) 7 or (CCGCCA) 1 (CCG) 10 repeat haplotype [31] . 
Notably, we have not observed the (CAACAG) 0 (CCGCCA) 0 (CCG) 12 , 
(CAACAG) 0 (CCGCCA) 0 (CCG) 10 , (CAACAG) 0 (CCGCCA) 0 (CCG) 7 or 
(CAACAG) 0 (CCGCCA) 1 (CCG) 10 disease-associated repeat haplotypes 
in our data. Nonetheless, we observed a similar effect size com- 
bining data from (CAACAG) 0 (Q 
2 = 0) disease associated alleles 
observed on three different (CCGCCA) P1 (CCG) P2 repeat haplotypes 
( Table 1 ). These data strongly suggest multiple origins for the 
CAACAG cassette deletion alleles (Q 2 = 0), and, that the size of 
the modifying effect of loss of the CAACAG cassette (Q 2 = 0) is 
overestimated due to the mis-sizing the pure CAG repeat tract 
(Q 1 ) by fragment length analysis and is not mediated by some 
other linked modiﬁer. The ﬁnding that fragment length analysis 
of HTT CAG length is inaccurate in subjects with atypical alle- 
les has implications for clinical trials with CAG repeat length 
inclusion criteria, potentially modifying the predicted AAO by 
from approximately −16 to + 3 years. These ﬁndings also have 
implications at the lower end of the disease-associated CAG 
range where discrepancies of + /- one to two CAG repeats could 
move an allele between the non-pathogenic and low pene- 
trance ranges, or between the low and fully penetrant ranges. 
As atypical disease-associated HTT alleles are relatively rare, 
additional larger and more detailed studies will be needed to 
better predict absolute effect sizes on HD outcomes for each 
speciﬁc structure. Nonetheless, these ﬁndings have implications 
for genetic diagnosis and counselling, and support a move toward 
sequence-based diagnosis and genetic stratiﬁcation in HD clinical 
trials. 
A possible explanation for the greater predictive power of pure 
CAG (Q 1 ) as opposed to total encoded-glutamine length (Q T ), is 
that somatic expansion of the CAG repeat is a driver of disease 
pathology. This interpretation is supported by the observation that 
somatic expansion scores in blood DNA were, as expected [1] , best 
predicted by the length of the pure CAG repeat (Q 1 ). Moreover, 
we were also able to determine that individuals with higher so- 
matic expansion scores in blood DNA, had worse clinical outcomes 
than average. In further support of a direct role for somatic expan- 
sions in mediating pathology in HD, we showed that some DNA 
repair gene variants revealed by GWAS to associate with HD out- 
comes [10,14,30] , also associate with somatic expansion scores in 
blood DNA, consistent with the role of these genes in generating 
expansions in model systems [1,32] . However, the effect for MSH3 
was modest and we were not able to detect associations with LIG1, 
PMS1 , and PMS2 , possibly as a limitation of the sample size. A role 
for somatic expansion in driving brain pathology is supported by 
the ﬁnding that a greater frequency of large expansions in the cor- 
tex of end-stage patients is associated with extreme early AAO in 
HD relative to that predicted using fragment length analysis (Q FL ) 
[33] . Thus, unless somatic expansions in blood DNA are directly 
impacting on primarily neurological disease outcomes, then the 
associations between somatic expansion scores in blood and dis- 
ease outcomes, suggest that the dynamics of HTT somatic expan- 
sion measured in blood broadly parallel those in the brain (Figure 
S6, appendix). Additional data are required to evaluate directly the 
degree of comparability between somatic expansion dynamics in 
blood and brain. A role for pure CAG length in driving pathology 
via somatic expansion may also apply to other disorders associ- 
ated with the expansion of polyglutamine-encoding repeats, such 
as SCA1, in which repeat interruptions also appear to modify dis- 
ease outcomes [34] . 
It is also possible that the greater predictive power of the pure 
CAG (Q 1 ) relative to the total number of consecutive encoded glu- 
tamines (Q T ) is not driven by somatic expansion, but other mech- 
anisms. These could include: i) there is an additional effect of 
linked variants, on, for instance, HTT transcription [29] ; ii) there 
are sequence-dependent effects on the HTT transcript, that might 
modify folding [35] , splicing [36] , or canonical translation [37] ; iii) 
there are sequence-dependent effects on RAN translation, possi- 
bly generating toxic polyalanine, polyserine, polyleucine or poly- 
cysteine proteins from the sense or antisense transcript [38] ; or, iv) 
the toxic element is not the encoded protein, but toxic RNA [39] . 
Somatic expansion ratios were best predicted by the length of 
the pure CAG repeat (Q 1 ) and in our data there was no additional 
stabilising effect of the number of copies of the CAACAG cassette. 
Indeed, after correcting for pure CAG (Q 1 ), there was a slight trend 
for additional copies of the CAACAG cassette to be associated with 
greater somatic expansion ratios. In contrast, Wright et al., have 
recently reported that the number of copies of the CAACAG cas- 
sette does directly modify somatic mutational dynamics in blood 
DNA [31] . However, it should be noted that their somatic expan- 
sion ratios have been corrected for the fragment length estimate 
of ‘CAG’, and not the number of pure CAG repeats (Wright and 
Hayden, personal communication) [31] . In addition, most of their 
data derive from the analysis of reduced penetrance alleles (36 to 
39 ‘CAG’ repeats). Larger studies will be required to further eval- 
uate possible interactions between pure CAG length (Q 1 ) and the 
number of copies of the CAACAG cassette on somatic expansions 
in blood DNA. 
Interestingly, correcting for pure CAG (Q 1 ) does not appear to 
completely eliminate the disease-moderating effect of the num- 
ber of additional glutamine codons (Q 2 ). This effect appeared to be 
more pronounced for the deletion of the CAACAG cassette (Q 2 = 0), 
than the duplication of the CAACAG cassette (Q 2 = 4). Nonetheless, 
if the polyglutamine protein is the toxic entity in cells, correcting 
for pure CAG would be expected to invert the disease-modifying 
effect of the number of copies of the CAACAG cassette, since alleles 
with more CAACAG cassettes will translate to proteins containing a 
greater total number of toxic glutamines (Figure S4, appendix). In 
addition to a contribution of the alternative mechanisms outlined 
above, explanations for this could also include: i) the number of 
additional CAA/CAG codons has an additional stabilising effect on 
somatic expansions in the brain, not reﬂected in somatic expan- 
sion scores in blood; or ii) somatically acquired disease-relevant 
expansions in brain are so large, that + / − two glutamines are not 
detectable/biologically relevant. 
Our data, the GWAS results [10,14,30] , and data on somatic ex- 
pansions in HD brains [ 4–6 , 33 ], converge on somatic expansion 
as a potential driver of disease pathology in HD. For the vari- 
ants in MLH1 and MSH3 , the directions of the effect in indepen- 
dent association studies [10,14,30] are consistent, i.e. the alleles 
we have associated with higher somatic expansion scores in blood 
DNA are associated with an earlier AAO [10] or more rapid dis- 
ease progression [14] . However, for the variants in MLH3 and FAN1 , 
the effect directions are not consistent, i.e. alleles associated with 
higher somatic expansion scores in blood DNA are associated with 
later AAO 10 or slower disease progression [14] . Notably, both the 
MLH3 and FAN1 SNPs are revealed as bidirectional tissue-speciﬁc 
expression quantitative trait loci in the human Genotype-Tissue 
Expression database [40] (Table S8, appendix) ( i.e. the same al- 
lele is associated with increased mRNA levels in some tissues and 
lower in others). Thus, the causative variant could mediate oppo- 
site effects on FAN1 / MLH3 expression and somatic expansion in 
the haematopoietic stem cells from which circulating white blood 
cells are derived, relative to the critical regions of the brain af- 
fected in HD (Figure S6, appendix). Tissue-speciﬁc effects of genetic 
modiﬁers might also explain the relatively modest associations 
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between disease outcomes and blood DNA somatic expansions 
scores, which, given the associations of DNA repair gene SNPs with 
disease outcomes [ 10 , 14 , 30 ], might reasonably have been expected 
to be more dramatic. Although confounded by the complexity of 
the underlying biology, our data nonetheless reveal somatic ex- 
pansion in blood as a potential peripheral biomarker of disease- 
relevant modiﬁers of somatic expansion for genetic studies and 
drug trials. To this end, longitudinal analyses of somatic expansion 
will be a key next step, in addition to the development of an assay 
that quantiﬁes somatic contractions. 
By associating genetic modiﬁers of HD outcomes to individual- 
speciﬁc somatic expansion scores, these data support somatic ex- 
pansion as a factor in HD pathogenesis and further highlight FAN1, 
MSH3, MLH3 and MLH1 and other components of the expansion 
pathway and/or the sequence integrity of the CAG repeat tract as 
potential therapeutic targets in this disorder. Although null alleles 
in some DNA mismatch repair genes, such as MLH1 and MSH2 [41] , 
have been associated with hereditary non-polyposis colon cancer, 
the common DNA repair gene polymorphisms analysed here are 
not associated with an overt cancer predisposition phenotype, yet 
are nonetheless associated with positive impacts on HD outcomes. 
This suggests that pharmacological interventions that achieved a 
similar impact on DNA repair activity might be therapeutically 
beneﬁcial and safe in HD and related repeat expansion disorders. 
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